OncoMatch/Clinical Trials/NCT05245656
A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma
Is NCT05245656 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including RB/RBAC alternating and RB for mantle cell lymphoma.
Treatment: RB/RBAC alternating · RB — This is a phase 2, multicenter, open-label, active-controlled randomized trial to determine efficacy and safety of rituximab/bendamustine (RB) alternating with rituximab/bendamustine/cytarabine (RBAC) compared with standard RB alone in the first-line treatment of elderly patients with mantle cell lymphoma, who are not eligible for high-dose therapy followed by autologous stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
histologically confirmed CD20+ mantle cell lymphoma
Disease stage
Excluded: Stage ANN ARBOR STAGE 1
Ann Arbor stage 1 disease [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any treatment for hodgkin lymphoma or non-hodgkin lymphoma
Lab requirements
Blood counts
absolute neutrophil counts (anc) ≥ 1,500/ml, platelet counts ≥ 100,000/ml (any anc and platelet counts are allowed, if they were related to bone marrow involvement)
Kidney function
serum creatinine ≤ 2.0mg/dl or crcl ≥40 ml/min based on the cockcroft-gault method
Liver function
≤2.5 times the upper limit of alt (≤5 times the upper limit of alt if the elevation is attributed by underlying lymphoma) and ≤2 times the upper limit of alt (≤3 times the upper limit of total bilirubin if the elevation is attributed by underlying lymphoma)
Cardiac function
lvef ≥50% by echocardiography or muga
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify